Proparacaine

Generic Name: Proparacaine

Brand Names: Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₂₆N_₂O_₃

CAS Number: 499-67-2

Unique Ingredient Identifier: B4OB0JHI1X

Background: Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.

Indication: Used as a local (ophthalmic) anesthetic.

Associated Conditions: Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Associated Therapies: Local Anaesthesia therapy

Clinical Trials

A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients

Phase 1

Recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Ruxolitinib Oral Tablet [Jakafi]
Drug: Lenalidomide
Drug: Methylprednisolone

First Posted Date: 2017-04-12

Last Posted Date: 2023-11-01

Lead Sponsor: Oncotherapeutics

Target Recruit Count: 134

Registration Number: NCT03110822

Locations: 🇺🇸
Global Oncology, Inc., Alhambra, California, United States
🇺🇸
Comprehensive Blood and Cancer Center, Bakersfield, California, United States
🇺🇸
Robert A. Moss, M.D., F.A.C.P., Inc., Fountain Valley, California, United States

and more 10 locations

Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone

Phase 2

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Isatuximab
Drug: Carfilzomib
Drug: Lenalidomide
Drug: Dexamethasone

First Posted Date: 2017-04-07

Last Posted Date: 2024-05-29

Lead Sponsor: Universitätsklinikum Hamburg-Eppendorf

Target Recruit Count: 246

Registration Number: NCT03104842

Locations: 🇩🇪
Vivantes Am Urban, Berlin, Germany
🇩🇪
Städt. Kliniken Bielefeld Klinikum Mitte, Bielefeld, Germany
🇩🇪
Campus Benjamin Franklin Charite Berlin, Berlin, Germany

and more 14 locations

Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-Risk Multiple Myeloma

Phase 1

Withdrawn

Conditions: Plasma Cell Leukemia in Remission
Plasma Cell Myeloma

Interventions: Procedure: Autologous Hematopoietic Stem Cell Transplantation
Drug: Cyclophosphamide
Biological: Filgrastim
Other: Laboratory Biomarker Analysis
Drug: Lenalidomide
Procedure: pheresis
Drug: Melphalan
Biological: Palifermin
Radiation: Total Marrow Irradiation

First Posted Date: 2017-04-04

Last Posted Date: 2017-12-13

Lead Sponsor: City of Hope Medical Center

Registration Number: NCT03100877

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States

Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma

Phase 1

Terminated

Conditions: Plasmacytoma
Recurrent Multiple Myeloma
Refractory Multiple Myeloma

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration and Biopsy
Drug: Carfilzomib
Drug: Dexamethasone
Drug: Dexamethasone Sodium Phosphate
Procedure: Echocardiography
Drug: Lenalidomide
Drug: Navtemadlin

First Posted Date: 2017-01-26

Last Posted Date: 2024-08-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 35

Registration Number: NCT03031730

Locations: 🇺🇸
NYP/Weill Cornell Medical Center, New York, New York, United States
🇺🇸
University of Texas at Austin, Austin, Texas, United States
🇺🇸
Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States

and more 4 locations

Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Mantle Cell Lymphoma
Recurrent Indolent Adult Non-Hodgkin Lymphoma
Refractory Indolent Adult Non-Hodgkin Lymphoma
Refractory Follicular Lymphoma
Recurrent Follicular Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma

Interventions: Procedure: Autologous Hematopoietic Stem Cell Transplantation
Drug: Carmustine
Biological: Cord Blood-derived Expanded Allogeneic Natural Killer Cells
Drug: Cytarabine
Drug: Etoposide
Biological: Filgrastim
Drug: Lenalidomide
Drug: Melphalan
Biological: Rituximab

First Posted Date: 2017-01-12

Last Posted Date: 2023-02-16

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 22

Registration Number: NCT03019640

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma

Phase 1

Active, not recruiting

Conditions: Grade 3a Follicular Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma
Recurrent Follicular Lymphoma
Recurrent Burkitt Lymphoma
Refractory Follicular Lymphoma
Refractory Lymphoplasmacytic Lymphoma
Recurrent Grade 1 Follicular Lymphoma
Recurrent Lymphoplasmacytic Lymphoma
Recurrent Mantle Cell Lymphoma
Recurrent Marginal Zone Lymphoma

Interventions: Other: Laboratory Biomarker Analysis
Drug: Lenalidomide
Biological: Nivolumab

First Posted Date: 2017-01-10

Last Posted Date: 2024-05-01

Lead Sponsor: David Bond, MD

Target Recruit Count: 36

Registration Number: NCT03015896

Locations: 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for Transplant

Phase 1

Terminated

Conditions: Recurrent Plasma Cell Myeloma
Refractory Plasma Cell Myeloma

Interventions: Drug: Dexamethasone
Drug: Ibrutinib
Other: Laboratory Biomarker Analysis
Drug: Lenalidomide
Other: Pharmacological Study
Other: Quality-of-Life Assessment

First Posted Date: 2017-01-10

Last Posted Date: 2023-03-07

Lead Sponsor: Mayo Clinic

Target Recruit Count: 18

Registration Number: NCT03015792

Locations: 🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States

Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple Myeloma

Phase 2

Completed

Conditions: Plasma Cell Myeloma

Interventions: Biological: Daratumumab
Drug: Dexamethasone
Drug: Ixazomib Citrate
Other: Laboratory Biomarker Analysis
Drug: Lenalidomide
Other: Questionnaire Administration

First Posted Date: 2017-01-06

Last Posted Date: 2024-06-21

Lead Sponsor: Mayo Clinic

Target Recruit Count: 80

Registration Number: NCT03012880

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma

Phase 1

Active, not recruiting

Conditions: Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma
Recurrent Mycosis Fungoides
Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma
Refractory Mycosis Fungoides
Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified
Sezary Syndrome
Folliculotropic Mycosis Fungoides
Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma

Interventions: Biological: Durvalumab
Other: Laboratory Biomarker Analysis
Drug: Lenalidomide

First Posted Date: 2017-01-05

Last Posted Date: 2024-10-29

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 38

Registration Number: NCT03011814

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States

and more 1 locations

A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma

Phase 2

Completed

Conditions: Lymphoma, Large B-Cell, Diffuse

Interventions: Drug: Durvalumab
Drug: Rituximab
Drug: Doxorubicin
Drug: Vincristine
Drug: Cyclophosphamide
Drug: Prednisone
Drug: Lenalidomide

First Posted Date: 2016-12-28

Last Posted Date: 2023-05-22

Lead Sponsor: Celgene

Target Recruit Count: 46

Registration Number: NCT03003520

Locations: 🇺🇸
Parkview Research Center, Fort Wayne, Indiana, United States
🇦🇹
Hanusch Krankenhaus, Wien, Austria
🇩🇰
Odense Universitetshospital, Odense C, Denmark

and more 17 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy